Combination Therapy in Lymphoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 August 2025 | Viewed by 3126
Special Issue Editors
Interests: lymphoma; lymphoma genomics; epigenetics; diffuse large B-cell lymphoma; marginal zone lymphoma; histone deacetylase inhibitors; anti-lymphoma agents; pre-clinical studies
Special Issues, Collections and Topics in MDPI journals
Interests: B cell lymphoma biology; marginal zone lymphoma; drug response and resistance; multi-omics characterization
Special Issue Information
Dear Colleagues,
We are pleased to invite you to this Special Issue on “Combination therapy in lymphoma”.
Combination chemotherapy, comprising alkylating and immunosuppressive agents, was for decades the standard of care for patients with Hodgkin and non-Hodgkin lymphomas. Combination therapy is therefore not a new concept in lymphoma treatment. The potential novelty in this field comes from the increasing arsenal of drugs being developed to treat lymphomas, many of which target specific proteins or reactivate anti-tumour immunity. At the end of the last century, arguably one of the most, if not the most, explosive addition to the lymphoma drug arsenal was the monoclonal antibody rituximab. The addition of rituximab to standard of care combination chemotherapy marked a practise-changing shift in the treatment of NHL and significantly improved outcomes for a larger fraction of these patients, including more complete remissions. For Hodgkin lymphoma, which already responded well to combined chemotherapy regimens, the advent of antibody drug conjugates and immune checkpoint inhibitors less than a decade ago further improved patient outcomes, nudging response rates close to 100%. These advances in lymphoma treatment have taught us the value of attacking tumour cells using a multi-pronged approach. As such, this Special Issue on ‘Combination therapy in lymphoma’ aims to highlight pre-clinical and clinical research investigating drug combinations for the treatment of lymphomas. Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: non-Hodgkin lymphoma, Hodgkin lymphoma, targeted agents, antibody drug conjugates, bispecific agents, cellular therapies, immune checkpoint inhibitors and epigenetic agents.
We look forward to receiving your contributions.
Dr. Afua Adjeiwaa Mensah
Dr. Alberto Arribas
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- combination therapy
- non-Hodgkin lymphoma
- Hodgkin lymphoma
- targeted agents
- antibody drug conjugates
- bispecific agents
- cellular therapies, immune checkpoint inhibitors and epigenetic agents
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
